Reuters
28 Jul 2026, 16:11 UTC · 13w ago
Recordati first-half core profit rises 8.8% on rare diseases
Impact · against what's priced in
Recordati's H1 core profit growth of 8.8% represents a positive earnings beat driven by its rare diseases segment. The growth in high-margin specialized medicines provides a catalyst for share price momentum.
- REC.MI+0.60
No priced-in read yet
- In context
The 8.8% rise in core profit to €540.2 million, specifically driven by the rare diseases segment, indicates strong operational execution and growth in high-margin verticals.
Read from the article alone
Top 1 mover · tap to explore
